Online inquiry

IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2878MR)

This product GTTS-WQ2878MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CCR4 gene. The antibody can be applied in Tropical spastic paraparesis, Adult T cell leukemia/lymphoma (ATL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005508.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1233
UniProt ID P51679
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ2878MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14808MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-70
GTTS-WQ7945MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ8162MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HL036337
GTTS-WQ11093MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCS-110
GTTS-WQ5527MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDP4940
GTTS-WQ14725MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-19A
GTTS-WQ13678MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RC18
GTTS-WQ11920MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MLN2045
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW